1-4 of 4
Elisabeth Wehrle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Clinical Trials & Observations
Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators
Journal: Blood
Blood (2010) 116 (19): 3758–3765.
https://doi.org/10.1182/blood-2010-03-273979
Published: 2010
Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD
Journal: Blood
Blood (2008) 112 (11): 334.
https://doi.org/10.1182/blood.V112.11.334.334
Published: 2008
Journal Articles

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group
Journal: Blood
Blood (2006) 108 (11): 2139.
https://doi.org/10.1182/blood.V108.11.2139.2139
Published: 2006
Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD
Journal: Blood
Blood (2005) 106 (11): 163.
https://doi.org/10.1182/blood.V106.11.163.163
Published: 2005